Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T79212 |
mTOR inhibitor-12
|
mTOR | PI3K/Akt/mTOR signaling |
mTORinhibitor-12(Compound 11)为选择性脑渗透性mTOR抑制剂,无遗传毒性风险,适用于中枢神经系统疾病研究。 | |||
T72374 | PI3K/mTOR Inhibitor-12 | PI3K | PI3K/Akt/mTOR signaling |
PI3K/mTOR Inhibitor-12为口服有效且选择性的PI3K/mTOR抑制剂,对PI3Kα和mTOR的IC50分别为0.06 nM及3.12 nM,表现出抗肿瘤活性且肝毒性较低。 | |||
T7166 |
GNE-493
|
PI3K; mTOR | PI3K/Akt/mTOR signaling |
GNE-493 是选择性的PI3K/mTOR 抑制剂,能够抑制 PI3Kα (IC50:3.4 nM),PI3Kβ (IC50:12 nM),PI3Kδ (IC50:16 nM),PI3Kγ (IC50:16 nM) 和 mTOR (IC50:32 nM)。 | |||
T2415 |
PP121
|
Apoptosis; VEGFR; Bcr-Abl; PDGFR; Src; mTOR; Hck | Angiogenesis; Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Tyrosine Kinase/Adaptors |
PP121是一种多靶点激酶抑制剂,抑制 PDGFR、Hck、mTOR、VEGFR2、Src、Abl、DNK-PK 的 IC50值分别为2、8、10、12、14、18、60 nM。 | |||
T1784 |
Everolimus
依维莫司,RAD001,SDZ-RAD |
Apoptosis; Others; mTOR; Autophagy | Apoptosis; Autophagy; Others; PI3K/Akt/mTOR signaling |
Everolimus (SDZ-RAD) 是 Rapamycin 的衍生物,也是一种口服活性的mTOR1选择性抑制剂。它与FKBP-12结合可产生免疫抑制复合物,还抑制肿瘤细胞增殖并诱导细胞凋亡和自噬,有免疫抑制和抗癌活性。 | |||
T63470 |
PI3K/mTOR Inhibitor-8
|
||
PI3K/mTOR Inhibitor-8 是 PI3K (PI3Kα IC50: 0.46 nM) 和 mTOR (mTOR IC50: 12 nM) 双重抑制剂。PI3K/mTOR Inhibitor-8 能够将 HCT-116 细胞的细胞周期阻滞在G1/S 期,并诱导其凋亡 (apoptosis)。 | |||
T61516 |
PI3K/mTOR Inhibitor-3
|
||
PI3K/mTOR Inhibitor-3 (compound 12) is an imidazoline compound with potent dual inhibitory effects on PI3K and mTOR. This compound exhibits notable anti-cancer activity [1]. | |||
T68485 | Apilimod HCl | ||
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions. It reduces the number of SARS-CoV-2-infected hiPSC-derived pneumocyte-like cells by 85% and inhibits SARS-CoV-2 replication in donor lung tissue. It also exhibits selective cytotoxicity in B-cell non-Hodgkin lymphoma ... |